Comparison of Effects of Controlled Onset Extended Release Verapamil at Bedtime and Nifedipine Gastrointestinal Therapeutic System on Arising on Early Morning Blood Pressure, Heart Rate, and the Heart Rate–Blood Pressure Product11A list of study investigators appears in the Appendix A.

White, William Β.; Black, Henry R.; Weber, Michael A.; Elliott, W.J.; Bryzinski, Brian; Fakouhi, T

doi:10.1016/s0002-9149(97)00935-1

Cited by 87 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have chosen a mean 24-h SBP of o5 mmHg as a definition of noninferiority. 12,13 In the present study, the difference in mean 24-h SBP between the two treatment groups was 3.8 mmHg, which falls within this definition.…”

Section: Discussionsupporting

confidence: 78%

“…A difference of 43 mmHg in the reduction of mean 24-h ambulatory DBP as the definition for noninferiority between telmisartan 80 mg vs losartan 50 mg/HCTZ 12.5 mg (the primary object of this study) was chosen based primarily on what had been used in previous studies. 12,13 The results of some studies, such as the UK Prospective Diabetes Study (UKPDS) and the Hypertension Optimal Treatment Study (HOT) 1,3 indicate a particular benefit of more intensive blood pressure reduction in hypertensive diabetics. However, in the overall HOT population, no differences were observed in cardiovascular event or mortality rates among the three target groups (whose DBP was lowered by 20.3, 22.3 and 24.3 mmHg, respectively).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM study

Neutel

Kolloch²,

Plouin

et al. 2003

J Hum Hypertens

View full text Add to dashboard Cite

The objective of this prospective, randomised, openlabel, blinded-end point parallel-group, multicentre study was to show that telmisartan 80 mg is not inferior to a fixed-dose combination of losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild-tomoderate hypertension. The criterion for noninferiority was a treatment difference of p3.0 mmHg in the reduction of 24-h mean ambulatory diastolic blood pressure (DBP) from the end of the 4-week placebo washout period to the end of the 6-week active treatment period. In the intent-to-treat analysis, the mean reduction in 24-h DBP was 8.3 7 6.7 mmHg among telmisartan-treated patients (n ¼ 332) and 10.3 7 6.3 mmHg among losartan/HCTZ-treated patients (n ¼ 350). The mean adjusted difference in 24-h DBP between the two treatment groups was 1.9 mmHg, allowing rejection of the a priori null hypothesis of a treatment difference of 43 mmHg. The reduction in mean 24-h systolic blood pressure was 13.2 7 10.2 mmHg with telmisartan and 17.1 7 10.3 mmHg with losartan/HCTZ. Both drugs provided effective control over the 24-h dosing interval. Analyses of morning (0600-1159) ambulatory blood pressure monitoring DBP means and trough cuff DBP confirmed the noninferiority hypothesis of the protocol for telmisartan 80 mg vs losartan 50 mg/HCTZ 12.5 mg. The reductions in office blood pressures measured at trough in patients treated with telmisartan were À16.3/À9.6 and À18.5/ À11.1 mmHg in the patients treated with losartan/HCTZ (difference À2.4/À1.2 mmHg). There were no differences between the side-effect profiles of the two treatments.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM study

Neutel

Kolloch²,

Plouin

et al. 2003

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…In a multicentre, randomized, double-blind clinical trial with a 10-week treatment period that compared the effects of controlled-onset extended release verapamil (314 mg/day) with a conventional, gastrointestinal nifedipine therapy (64 mg/day), arthralgia was more frequent in the nifedipine group (6%) than in the verapamil group (2%); and the difference was statistically significant (p=0.048) [55]. However, increased frequencies of joint pain have not been reported in other studies [56].…”

Section: Clinical Data On the Effects Of Vdcc Inhibitors In Oa Patientsmentioning

confidence: 99%

Voltage-Dependent Calcium Channels in Chondrocytes: Roles in Health and Disease

2015

View full text Add to dashboard Cite

Chondrocytes, the single cell type in adult articular cartilage, have conventionally been considered to be non-excitable cells. However, recent evidence suggests that their resting membrane potential (RMP) is less negative than that of excitable cells, and they are fully equipped with channels that control ion, water, and osmolyte movement across the chondrocyte membrane. Among calcium-specific ion channels, members of the voltage-dependent calcium channel (VDCC) family are expressed in chondrocytes where they are functionally active. Ltype VDCC inhibitors such as nifedipine and verapamil have contributed to our understanding of the roles of these ion channels in chondrogenesis, chondrocyte signalling, and mechanotransduction. In this narrative review, we discuss published data indicating that VDCC function is vital for chondrocyte health, especially in regulating proliferation and maturation.We also highlight the fact that activation of VDCC function appears to accompany various inflammatory aspects of osteoarthritis (OA) and, based on in vitro data, the application of nifedipine and/or verapamil may be a promising approach for ameliorating OA severity.However, very few studies on clinical outcomes are available regarding the influence of calcium antagonists, which are used primarily for treating cardiovascular conditions in OA patients. This review is intended to stimulate further research on the chondrocyte 'channelome', contribute to the development of novel therapeutic strategies, and facilitate the retargeting and repositioning of existing pharmacological agents currently used for other comorbidities for the treatment of OA.

show abstract

“…17 These results with NOP were similar in other studies in which there was an increase of the HR and of the double product in the morning hours. 18 The therapeutic efficacy of the osmotic pump nifedipine has been fully established. 5,6 In this study, it is compared with nifedipine with another form of release by microgranules which enables a slow release, used as monotherapy for high blood pressure and stable effect for 24 h, with the same dose once a day, for which ABPM is used with the calculation and measurement of MAP in 24 h, minimising the variability of BP when comparing both formulations.…”

Section: Discussionmentioning

confidence: 99%

Blood pressure response in 24 hours in patients with high blood pressure treated with two nifedipine formulations once a day

Rodríguez-Roa¹,

Octavio

Mayorca³

et al. 2002

J Hum Hypertens

View full text Add to dashboard Cite

A double-blind, comparative and prospective study with nifedipine once a day was undertaken, in patients with mild and moderate high blood pressure. Blood pressure was measured by mercury sphygmomanometer in two positions: resting and sitting at 3, 6 and 12 weeks of treatment and by ambulatory blood pressure monitoring (ABPM) over 24 h; both were carried out before and after the treatment and the uniformity in the pressure levels were obtained by means of the Smoothness Index. Fiftyfour patients were included in the trial, 28 in the microgranules group and 26 in the osmotic pump group. These groups were similar at the baseline in age, gender, weight, height, diastolic and systolic blood pressure. The nifedipine microgranules group had a heart rate higher than the nifedipine osmotic pump group at baseline (X M = 75.58 vs X B = 70.75). Blood pressure decreased significantly during the first 3 weeks; 85% in

show abstract

Comparison of Effects of Controlled Onset Extended Release Verapamil at Bedtime and Nifedipine Gastrointestinal Therapeutic System on Arising on Early Morning Blood Pressure, Heart Rate, and the Heart Rate–Blood Pressure Product11A list of study investigators appears in the Appendix A.

Cited by 87 publications

References 24 publications

Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM study

Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM study

Voltage-Dependent Calcium Channels in Chondrocytes: Roles in Health and Disease

Blood pressure response in 24 hours in patients with high blood pressure treated with two nifedipine formulations once a day

Contact Info

Product

Resources

About